Steven Stein
Direttore Tecnico/Scientifico/R&S presso INCYTE CORPORATION
Patrimonio netto: 5 M $ in data 30/04/2024
Posizioni attive di Steven Stein
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| INCYTE CORPORATION | Direttore Tecnico/Scientifico/R&S | 02/03/2015 | - |
Israel Biotech Fund
 Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Consulente / Consigliere | - | - |
| University of Pennsylvania | Corporate Officer/Principal | - | - |
Storia della carriera di Steven Stein
Precedenti posizioni note di Steven Stein
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| THESEUS PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 17/10/2022 | 14/02/2024 |
| Independent Dir/Board Member | 17/10/2022 | 14/02/2024 | |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 01/05/2011 | 01/02/2015 |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 01/05/2011 | 01/02/2015 |
| GlaxoSmithKline (New Jersey) | Corporate Officer/Principal | 01/02/2004 | 01/04/2011 |
| KURA ONCOLOGY, INC. | Direttore/Membro del Consiglio | 03/01/2017 | - |
| Independent Dir/Board Member | 03/01/2017 | - |
Formazione di Steven Stein
| University of the Witwatersrand | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 8 |
| Sud Africa | 2 |
| Israele | 2 |
Posizioni
| Corporate Officer/Principal | 4 |
| Director/Board Member | 2 |
| Independent Dir/Board Member | 2 |
Settori
| Health Technology | 6 |
| Consumer Services | 3 |
| Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| KURA ONCOLOGY, INC. | Health Technology |
| Aziende private | 5 |
|---|---|
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Health Technology |
| GlaxoSmithKline (New Jersey) | |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Finance |
Theseus Pharmaceuticals, Inc.
 Theseus Pharmaceuticals, Inc. BiotechnologyHealth Technology Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Steven Stein
- Esperienza